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Sodium glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antidiabetic 
drugs for the treatment of type 2 diabetes mellitus (T2DM) (1). In addition to their 
hypoglycemic effect, SGLT2 inhibitors also offer several beneficial effects, such as 
weight loss and blood pressure reduction (1). However, the overall health benefits of 
these drugs needed to outweigh their possible side-effects. Recently, cumulative 
evidence suggests that SGLT2 inhibitors may lead to diabetic ketoacidosis (DKA), which 
is a serious acute complication of diabetes mellitus (2, 3). In May 2015, the U.S. Food 
and Drug Administration (FDA) issued an updated drug safety communication warning 
about SGLT2 inhibitors potentially increasing the risk of DKA (4). Since DKA is a rare 
adverse effect, the evidence from individual studies or simply pooling the numbers from 
multiple reports is generally weak. We therefore conducted a meta-analysis of 
randomized controlled trials (RCTs) to examine whether SGLT2 inhibitors affect the risk 
of DKAs in patients with T2DM.  
We searched PubMed, Embase, Cochrane Central Register of Controlled Trials 
(CENTRAL) and ClinicalTrials.gov from inception to January 27, 2016 to identify the 
published and unpublished RCTs of SGLT2 inhibitors that reported DKA events in 
patients with T2DM. Two reviewers independently performed the study selection, data 
extraction, and quality assessment. A Peto odds ratio (OR) with 95% confidence interval 
(CI) using a random-effects model was used due to very low event rate. The I² statistic 
was used to detect the possible between-study heterogeneity. All statistical analyses 
were performed with STATA version 14. 
A total of 10 eligible RCTs involving 13,134 patients and 14 DKA events were identified 
from 1,268 citations. Overall, the event rates were 0.1% in the group of SGLT2 inhibitor 
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users versus 0.06% in the control groups. The meta-analysis results are shown in the 
Fig.1. SGLT2 inhibitors were not associated with significantly higher risk of DKA than 
control group (OR, 1.71; 95%CI 0.56 to 5.20). Furthermore, our subgroup analyses 
showed that SGLT2 inhibitors were not significantly associated with increased risk of 
DKA when compared with placebo (OR 1.98; 95% CI 0.56 to 6.94) or dipeptidyl 
peptidase 4 (DPP-4) inhibitors (OR 1.00; 95%CI 0.09 to 11.01). No statistical 
heterogeneity was observed all the analyses except for the subgroup analysis of SGLT2 
inhibitors versus DPP-4 inhibitors (I²=66.7%).  
Previous trials reported increased DKA cases with the use of SGLT2 inhibitors, 
especially when they were used off-label in patients with type 1 diabetes mellitus (2, 3). 
Some plausible mechanisms are already proposed by which SGLT2 inhibitors might 
trigger DKA (3, 5). Based on current evidence from RCT data, we found that SGLT2 
inhibitors were not significantly associated with an increased risk of DKA among patients 
with T2DM. Consistent with previous report (5), the frequency of reported DKA events 
related to SGLT2 inhibitor treatment in T2DM patients is less than 0.1%.By synthesizing 
cumulative evidence from RCTs, our study, however, did not support the adverse effect 
on DKA among T2DM patients. Although the null results presented the highest strength 
of evidence from available RCT data, we cannot rule out the possibilities of a modest 
effect on DKA by SGLT2 inhibitors, an effect on a specific clinical phenotype of DKA (e.g. 
euglycemic DKA), or a non-class effect. There is some evidence indicating that the risk 
of euglycemic DKA related to SGLT2 inhibitors may be increased among long-standing 
T2DM patients with marked β-cell insufficiency, in latent autoimmune diabetes, or under 
other severe medical conditions (5). In this regard, further safety monitoring based on 
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larger number of cases and detailed clinical information on related DKA cases is 
warranted to resolve uncertainty about this specific drug safety issue.  
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Figure Legend:   
Figure 1- Meta-analysis of SGLT2 inhibitors on the risk of diabetic ketoacidosis. SGLT2 
inhibitors, Sodium glucose cotransporter 2 inhibitors; DPP-4 inhibitors, dipeptidyl 
peptidase 4 inhibitors.   
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Figure 1 
  
